Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is a promising biotech company with a strong focus on developing treatments for aging-related diseases and chronic inflammation. Their lead drug, BGE-102, has shown promising results and they have established collaborations with major players in the pharmaceutical industry. The company's emphasis on developing oral small molecule therapies is a strength, although there are inherent risks in drug development. Their robust financial position and upcoming catalysts make them a favorable investment, and their potential in utilizing health data for treatment analysis and identification of new targets is also a promising aspect. However, competition in the market and potential setbacks in drug development pose risks to their success.

Bears say

Bioage Labs is a biopharmaceutical company focused on developing drugs to treat metabolic diseases by targeting the biology of human aging. Despite partnerships with big pharmaceutical companies like Novartis and Lilly, the company faces multiple challenges, including the risk of failure in clinical trials, intellectual property challenges, and strong competition from established players in the market. Additionally, their drugs may have limited efficacy compared to other emerging treatments for metabolic diseases. As a financial analyst, I have a negative outlook on their stock due to these fundamental risks.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.